Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based assays, FISH testing and other molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, “Methods and materials for classification of tissue of origin of tumor samples.”
Flagship Biosciences and Advanced Cell Diagnostics Collaborate to Develop Quantitative RNAscope Assays for Pharmaceutical Clinical Trials in the CLIA Environment
Flagship Biosciences, the leading service provider of tissue image analysis solutions, recently announced the utilization of its wet assay development and image analysis quantification capabilities for RNAscope® RNA in situ hybridization (ISH) from Advanced Cell Diagnostics, Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based analysis tools. The two companies will work to optimize quantitative image analysis of in situ hybridization in tissue samples in Flagship’s CLIA laboratory.
Millions of times a year, teams at the University of Michigan Health System test samples of tissue, blood and other bodily fluids for patients of all ages. The results can reveal risks or signs of disease — or response to treatment — and help make a major difference in doctors’ decisions.
OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation recently announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx™, OncoCyte’s non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The clinical data was presented by Maria Prendes, PhD, Director of Manufacturing at OncoCyte, at the American Association for Cancer Research (AACR) Annual Meeting during a poster presentation from 8:00 AM -12:00 PM EDT on Monday, April 20, 2015.
Pharmaceutical Product Development, LLC (PPD) has opened a central laboratory in Shanghai, China, to deliver global scientific and technical laboratory expertise to meet growing client demand for these services in China. The new facility, which has been established in association with Shanghai Clinical Research Center (SCRC), is equipped with cutting-edge analytical equipment to provide high-quality data across a wide range of technologies and applications for all phases of pharmaceutical development.